Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more
Alto Neuroscience, Inc. (ANRO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.089x
Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has a cash flow conversion efficiency ratio of -0.089x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.92 Million) by net assets ($111.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alto Neuroscience, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Alto Neuroscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alto Neuroscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alto Neuroscience, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EQ Resources Ltd
AU:EQR
|
-0.351x |
|
Shanghai Hajime Advanced Material Technology Co. Ltd.
SHE:301000
|
0.018x |
|
Shanghai Sinotec Co Ltd
SHG:603121
|
0.048x |
|
Tian Jin Global Magnetic Card Co Ltd
SHG:600800
|
-0.002x |
|
Zhangjiagang Freetrade Science and Technology Co Ltd
SHG:600794
|
-0.023x |
|
Bandwidth Inc
NASDAQ:BAND
|
0.057x |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
0.059x |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
0.008x |
Annual Cash Flow Conversion Efficiency for Alto Neuroscience, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Alto Neuroscience, Inc. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $151.46 Million | $-47.42 Million | -0.313x | -167.09% |
| 2023-09-30 | $-71.67 Million | $-33.45 Million | 0.467x | -12.11% |
| 2022-09-30 | $-38.41 Million | $-20.39 Million | 0.531x | -28.46% |
| 2021-09-30 | $-12.48 Million | $-9.26 Million | 0.742x | -- |